STOCK TITAN

OPTIMI HEALTH CORP - OPTHF STOCK NEWS

Welcome to our dedicated page for OPTIMI HEALTH news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on OPTIMI HEALTH stock.

Optimi Health Corp. (OPTHF) is a leading Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA. The company recently obtained a Drug Establishment Licence (DEL) from Health Canada, confirming compliance with Good Manufacturing Practices (GMP). This allows Optimi to supply MDMA and psilocybin capsules to patients with PTSD and Treatment-Resistant Depression under Australia's Authorized Prescriber Scheme and export to regulated jurisdictions globally. Optimi aims to be the trusted global supplier of safe drug candidates by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.

Rhea-AI Summary

Optimi Health Corp has submitted a request to Health Canada for an amendment to its Controlled Substances Dealer’s Licence to synthesize and distribute pharmaceutical-grade MDMA at its facility in Princeton, British Columbia. This move is part of the company’s strategy to commercialize synthetic psychedelics, capitalizing on growing demand in research, especially from Phase III MDMA studies led by MAPS. Optimi aims to expand its offerings and improve revenue generation through standardized drug testing and clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. (OTCQX: OPTHF) has entered a strategic supply agreement with ATMA Journey Centers to provide psilocybin products for therapist training and therapy initiatives. This partnership aims to improve regulatory outcomes and enhance mental health services. Optimi will supply high-quality psilocybin to support research and training for therapists, contributing to the evolving landscape of psilocybin-assisted therapy. The collaboration is expected to refine commercial distribution and clinical applications of psilocybin, preparing for increasing demand as research advances.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
partnership
-
Rhea-AI Summary

Optimi Health Corp. (OTCQX: OPTHF) has announced a one-year supply agreement with Filament Health for psilocybin mushrooms cultivated at its EU-GMP facility in Princeton, British Columbia. The deal allows Filament to order whole, dried mushroom fruiting bodies for drug development purposes. Both companies aim to enhance the safety and supply of natural psilocybin, which is actively being studied in clinical trials worldwide. This collaboration aligns with Optimi's goal to be a trusted provider of safe, natural psilocybin and functional mushrooms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.94%
Tags
none
Rhea-AI Summary

Optimi Health Corp. (OTCQX: OPTHF) has announced a supply agreement with Halucenex Life Sciences Inc. for the provision of its first batch of psilocybe cubensis mushrooms, harvested from its facility in Princeton, British Columbia. This agreement is a significant step following Optimi's initial cultivation cycle and aims to meet the growing demand for GMP-grade psilocybin. The company has received a dealer's license allowing possession of up to 5000 kg of dried psilocybin mushrooms. This partnership supports Halucenex's research into psychedelic-assisted therapy for PTSD and anxiety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.58%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. (OTCQX: OPTHF) announced a significant milestone with the successful completion of its first batch of psilocybin cubensis and functional mushrooms. Based in Vancouver, Canada, Optimi is focused on scalable mushroom cultivation aimed at addressing mental health issues. With enhancements from new genetics and a revised Health Canada Dealer’s Licence, the company plans to expand its domestic and international supply agreements. CEO Bill Ciprick emphasized the operational capacity achieved and the commitment to addressing mental health crises through its products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. is set to host a grand opening for its new psilocybin cultivation facility in Princeton, British Columbia, on May 27, 2022. Crispin Blunt, UK Conservative MP and advocate for psilocybin rescheduling, will speak on the mental health benefits of psilocybin. The facility, spanning 20,000 square feet, aims to produce EU-GMP grade psilocybin and functional mushrooms for wellness markets. Optimi has secured a research exemption and dealer's license for psilocybin use, aligning with its mission to lead in safe psychedelic therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
Rhea-AI Summary

Optimi Health Corp. has acquired a diverse catalog of psilocybin and functional mushroom strains, expanding its genetic bank significantly. The acquisition, involving 24 psychedelic and nine functional strains, supports its goal of producing safe, EU-GMP psilocybin in its 20,000 square-foot facility in Princeton, British Columbia. This move allows Optimi to provide products for clinical trials and Canada’s Special Access Program. The company aims to enhance research in mental health treatment, positioning itself as a leading supplier in the burgeoning psychedelic industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
-
Rhea-AI Summary

Optimi Health Corp has completed the expansion of its analytical laboratory located in Princeton, British Columbia, designed to ensure consistent dosages of natural psilocybin products meeting FDA and EU-GMP standards. The lab, overseen by Chief Science Officer Justin Kirkland, aims to enhance research capabilities and support clients in drug discovery processes. CEO Bill Ciprick emphasized the importance of this facility for operationalizing psychedelic science and the company's revenue strategy. Optimi aims to lead in supplying safe, high-quality psilocybin mushrooms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.94%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. (OTCQX: OPTHF) announced its support for Health Canada's Notice on psilocybin mushrooms, highlighting the importance of drug quality and GMP standards. CEO Bill Ciprick emphasized the company's commitment to producing natural psilocybin and functional mushrooms from its advanced facilities. Optimi is positioned to become a leader in this market, having received permission to handle large quantities of psilocybin. The company will also celebrate the grand opening of its Princeton facility on May 27, inviting stakeholders from various sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
none
Rhea-AI Summary

Optimi Health Corp. has received approval from Health Canada to modify its Controlled Substances Dealer’s Licence, allowing for an expanded capacity to produce psilocybin and psilocin at its Princeton facility. The amendment permits possession of up to 5,000 kg of dried psilocybin mushrooms and 100 g of psilocin, aiming to support clinical trials for addiction and mental health treatments. The company’s facility now comprises 20,000 square feet of advanced aeroponics systems. Optimi plans a grand opening event on May 27, 2022, inviting the local community and stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none

FAQ

What is the current stock price of OPTIMI HEALTH (OPTHF)?

The current stock price of OPTIMI HEALTH (OPTHF) is $0.152 as of December 24, 2024.

What is the market cap of OPTIMI HEALTH (OPTHF)?

The market cap of OPTIMI HEALTH (OPTHF) is approximately 14.6M.

What is Optimi Health Corp. specialized in?

Optimi is a Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances like botanical psilocybin and MDMA.

What recent milestone did Optimi achieve?

Optimi obtained a Drug Establishment Licence (DEL) from Health Canada, affirming its compliance with Good Manufacturing Practices (GMP) to supply MDMA and psilocybin capsules for patients.

What is Optimi's goal in the pharmaceutical industry?

Optimi aims to be the top trusted supplier of safe drug candidates globally by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.

Where is Optimi's manufacturing facility located?

Optimi's manufacturing facilities totaling 20,000 square feet are located in Princeton, British Columbia.

What licenses does Optimi hold?

Optimi holds a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL), enabling the production of GMP-grade products and APIs.

How does Optimi plan to support global psychedelic research?

Optimi has completed its first international shipment of MDMA to Israel, supporting global research and innovation in the psychedelic field.

What is Optimi's key achievement in terms of export?

Optimi received the necessary Export Permit from Health Canada, confirming its ability to export controlled substances internationally.

What services does Oak Hill Financial Inc. provide to Optimi?

Oak Hill Financial Inc. provides comprehensive investor relations, business, and capital markets advisory services to Optimi at a rate of CDN$12,000 per month.

How does Optimi plan to expand its shareholder base?

Optimi aims to engage new investors and communicate its corporate milestones effectively through partnerships like Oak Hill Financial Inc.

What makes Optimi unique in the pharmaceutical industry?

Optimi's unique capabilities lie in producing scalable psychedelic formulations for transformational human experiences while meeting the highest quality and safety standards.

OPTIMI HEALTH CORP

OTC:OPTHF

OPTHF Rankings

OPTHF Stock Data

14.58M
58.12M
16.52%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Garibaldi Highlands